Tenax Therapeutics Inc（TENX）股票分析TENXTenax Therapeutics Inc

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tenax Therapeutics is not a good buy right now. The current price is $1.68, which is significantly lower than the 52-week high of $19.40, reflecting a staggering 84.75% year-to-date decline. The company's forward P/E ratio is 0.299, suggesting potential undervaluation, but the negative sentiment from analysts and the company's ongoing financial losses, including a net income loss of $15.7 million in Q1 2026, raise serious concerns about its viability and future growth prospects.

1 analysts cover TENX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.